Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan

Clinical Therapeutics

Volumn 32, Issue 2, 2010, Pages 311-326

  Ishiguro, Hiroshi ^a   Kondo, Masahide ^b,c   Hoshi, Shu Ling ^b   Takada, Masahiro ^a   Nakamura, Seigo ^d   Teramukai, Satoshi ^a   Yanagihara, Kazuhiro ^a   Toi, Masakazu ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

Author keywords

breast cancer; budget impact; chemotherapy; cost effectiveness; febrile neutropenia; G CSF

Indexed keywords

ANASTROZOLE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GONADORELIN; GRANULOCYTE COLONY STIMULATING FACTOR; MEDROXYPROGESTERONE ACETATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; JAPAN; PRESCRIPTION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG COSTS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; JAPAN; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; NEOPLASM RECURRENCE, LOCAL; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77649090591     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.01.029     Document Type: Article

References (41)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 365 (2005) 1687-1717
2. Citron M.L., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 [published correction appears in J Clin Oncol. 2003;21:2226]. J Clin Oncol. 21 (2003) 1431-1439
3. Martin M., Pienkowski T., Mackey J., et al., Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 352 (2005) 2302-2313
4. Martfn M., Lluch A., Seguf M.A., et al. Toxicity and health-related quality of life in breast cancer patients re-ceiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol. 17 (2006) 1205-1212
5. Jones S., Holmes F.A., O'Shaughnessy J., et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-Year follow-up of US Oncology Research Trial. J Clin Oncol. 27 (2009) 1177-1183
6. Tashiro H., Sagara T., Okada K., et al. The safety of docetaxel with cyclophosphamide (TC) therapy as adjuvant chemotherapy for Japanese women with operable breast cancer. Jap J Cancer Chemother. 34 (2007) 393-396
7. Center for Cancer Control and Information Services, National Cancer Center. Japan 2007 graph database. http://ganjoho.jp/pro/statistics/en/graph_db_index.html Accessed July 6, 2009
8. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 24 (2006) 3187-3205
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Myeloid growth factors, V.1. 2009. http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf Accessed January 4, 2010
10. The Japanese Breast Cancer Society. Drug therapy 2007. The evidence based breast cancer practice guideline part 1 [in Japanese] (2007), Kanehara-Shuppan, Tokyo, Japan
11. Klijn J.G., Blamey R.W., Boccardo F., et al., Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol. 19 (2001) 343-353
12. Nabholtz J.M., Bonneterre J., Buzdar A., et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Survival analysis and updated safety results. Eur J Cancer. 39 (2003) 1684-1689
13. Thürlimann B., Hess D., Köberle D., et al. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95-a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat. 85 (2004) 247-254
14. Seidman A.D., Berry D., Cirrincione C., et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 26 (2008) 1642-1649
15. Xeloda (capecitabine) [package insert] (2006), Roche Pharmaceuticals, Nutley, NJ
16. Zelek L., Barthier S., Riofrio M., et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in meta-static breast carcinoma. Cancer. 92 (2001) 2267-2272
17. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344 (2001) 783-792
18. Bartsch R., Wenzel C., Altorjai G., et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 25 (2007) 3853-3858
19. Suzuki Y., Tokuda Y., Saito Y., et al. Combination of trastuzumab and vinorelbine in metastatic breast cancer. Jpn J Clin Oncol. 33 (2003) 514-517
20. Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, and Labour and Welfare. Ethical guidelines for epidemiological research (17 June 2002). http://www.niph.go.jp/english2/english%20ver/ethical-gl/guidelines.htm Accessed November 22, 2009
21. Goldhirsch A., Wood W.C., Gelber R.D., et al. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007 [published correction appears in Ann Oncol. 2007;18:1917]. Ann Oncol. 18 (2007) 1133-1144
22. The Japanese Breast Cancer Society. Japanese breast cancer patient registration report: Confirmed cases for 2004 [in Japanese]. http://www.jbcs.gr.jp/people/2004nenji.pdf Accessed July 6, 2009
23. Au H.J., Golmohammadi K., Younis T., et al. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: Modeling the downstream effects. Breast Cancer Res Treat. 114 (2009) 579-587
24. Hayman J.A., Hillner B.E., Harris J.R., and Weeks J.C. Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J Clin Oncol. 16 (1998) 1022-1029
25. Marchetti M., Caruggi M., and Colombo G. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: A literature-based model analysis of costs in the Italian National Health Service. Clin Ther. 26 (2004) 1546-1561
26. Dranitsaris G., Verma S., and Trudeau M. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: Comparison of two aromatase inhibitors to tamoxifen. Am J Clin Oncol. 26 (2003) 289-296
27. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf Accessed January 26, 2010
28. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis, V.4. 2009. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf Accessed January 4, 2010
29. Garcia-Carbonero R., Mayordomo J.I., Tornamira M.V., et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial. J Natl Cancer Inst. 93 (2001) 31-38
30. Shiroiwa T., Fukuda T., and Tsutani K. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther. 29 (2007) 2256-2267
31. Shiroiwa T., Fukuda T., Shimozuma K., et al. The model-based costeffectiveness analysis of 1-year adjuvant trastuzumab treatment: Based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 109 (2008) 559-566
32. Kondo M., Hoshi S.L., and Toi M. Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. Br J Cancer. 100 (2009) 281-290
33. Adjuvant! Online. Adjuvant! breast cancer help files (breast cancer standard version). http://www.adjuvantonline.com/breasthelp0306/breastindex.html Accessed January 4, 2010
34. Marugame T., Matsuda T., Kamo K., et al., Japan Cancer Surveillance Research Group. Cancer incidence and incidence rates in Japan in 2001 based on the data from 10 population-based cancer registries. Jpn J Clin Oncol. 37 (2007) 884-891
35. Ohkusa Y. Empirical research for the critical value of expenditure per QALY [in Japanese]. Iryo To Syakai. 13 (2003) 121-130
36. Ministry of Health, Labour and Welfare. National Health Care Expenditure 2006 [in Japanese] (2008), Health & Welfare Statistics Association, Tokyo, Japan
37. Wolowacz S.E., Cameron D.A., Tate H.C., and Bagust A. Docetaxel in combination with doxorubicin and cyclo-phosphamide as adjuvant treatment for early node-positive breast cancer: A cost-effectiveness and cost-utility analysis. J Clin Oncol. 26 (2008) 925-933
38. Tengs T.O. Cost-effectiveness versus cost-utility analysis of interventions for cancer: Does adjusting for health-related quality of life really matter?. Value Health. 7 (2004) 70-78
39. Oyama A., Ota K., Asano S., et al. A double-blind, cross-over clinical trial of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma [in Japanese]. Nippon Gan Chiryo Gakkai Shi. 25 (1990) 2533-2548
40. Ogawa M., Masaoka T., Mizoguchi H., et al. A phase III study of KRN 8601 (rhG-CSF) on neutropenia induced by chemotherapy for malignant lymphoma-a multiinstitutional placebo controlled double-blind comparative study [in Japanese]. Gan To Kagaku Ryoho. 17 (1990) 365-373
41. Kimura I., Ohonoshi T., Okabe T., et al. Clinical trial of KRN 8601 in patients with neutropenia induced by chemotherapy for lung cancer [in Japanese]. Gan To Kagaku Ryoho. 17 (1990) 999-1003